4.8 Article

IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis

期刊

HEPATOLOGY
卷 76, 期 4, 页码 1058-1068

出版社

WILEY
DOI: 10.1002/hep.32478

关键词

-

资金

  1. National Institutes of Health [1P50AA024337, P50 AA024333, R21 AR 071046, RO1 AA028190, RO1 DK113196, RO1 GM119174, U01 AA026977, U01AA021890, U01AA021901, U01AA026938, UH3 AA026970, UO1 AA021890, UO1 AA023902, UO1 AA026933, UO1 AA026976, UO1 AA026976-03S1]

向作者/读者索取更多资源

Combination therapy of anakinra, pentoxifylline, and zinc provides similar survival benefits compared to corticosteroid therapy in severe alcohol-associated hepatitis.
Background and Aims Patients with severe alcohol-associated hepatitis (AH) have high mortality. Corticosteroids improve survival only for 30 days. We targeted inflammation, cellular injury, and gut leakiness in a randomized clinical trial comparing combination therapy to corticosteroids on 180-day survival. Approach and Results Subjects with a clinical diagnosis of severe AH (Model for End-Stage Liver Disease [MELD] >20, Maddrey discriminant function [MDF] >32) were randomized to receive methylprednisolone (PRED; 28 days) or a combination of anakinra (14 days) plus pentoxifylline (28 days) plus zinc (COMB; 180 days). The primary endpoint was survival at 180 days. The study was designed in 2013, initiated in October 2014, and completed in March 2018. Five hundred patients were screened to randomize 104 subjects with a clinical diagnosis of AH with a MELD score >20. Fifty-three patients were randomized into the COMB and 50 to the PRED treatment; 1 dropped out of the study before randomization. Mean age was 45.3 +/- 10.4 years; 60.6% were males, 92.3% White, and mean MELD 25.7 +/- 3.9. Kaplan-Meier survival estimate at 180 days was 67.9% in COMB and 56% in PRED (HR = 0.69; p = 0.3001). Survival curves separated by 90 days (COMB, 69.8%; PRED, 58.0%; HR = 0.69; p = 0.28). Survival at 28 days was similar between the COMB (83.4%) and PRED groups (81.2%; HR = 0.91; p = 0.85). There were no unexpected serious adverse events, and incidence of infection was comparable between groups. MELD 20-25 and MELD >26 strata showed nonsignificant treatment effects in favor of COMB. Conclusions A combination of anakinra, pentoxifylline plus zinc provides similar survival benefits compared to corticosteroid therapy in severe AH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据